Avalo Therapeutics (AVTX)
NASDAQ:AVTX
Top Page
Avalo Therapeutics
(NASDAQ:AVTX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$14.00
▲(2.49% Upside)
Action:ReiteratedDate:04/09/26
The score is primarily held back by very weak financial performance (minimal/declining revenue, large losses, and significant cash burn). Technical signals also lean bearish with the stock below key moving averages and a negative MACD. A positive offset comes from a notable pipeline milestone (Phase 2 enrollment complete with Q2 2026 data), but it does not fully counterbalance the current financial and momentum risks.
Positive Factors
Pipeline Progress
Completing Phase 2 enrollment materially reduces development execution risk and provides a clear near-term clinical readout that can validate AVTX-009’s biology. A positive or informative topline can unlock partnering options, de-risk later-stage investment decisions and guide next-stage resource allocation.
Negative Factors
High Cash Burn
Sustained negative operating and free cash flow at ~-$51M annually consumes liquidity and forces recurring funding decisions. Persistent burn pressures strategic flexibility, increases dependency on equity markets or partnerships, and can dilute existing shareholders or delay programs if financing terms are unfavorable.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline Progress
Completing Phase 2 enrollment materially reduces development execution risk and provides a clear near-term clinical readout that can validate AVTX-009’s biology. A positive or informative topline can unlock partnering options, de-risk later-stage investment decisions and guide next-stage resource allocation.
Read all positive factors
Avalo Therapeutics (AVTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$311.29M
Dividend YieldN/A
Average Volume (3M)826.05K
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue Growth-76.59%
EPS Growth94.03%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.75
Shares Outstanding22,788,452
10 Day Avg. Volume862,934
30 Day Avg. Volume826,051
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)2.93
Price to Sales (P/S)4125.96
P/FCF Ratio-4.73
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue2.33K
Enterprise Value/Gross Profit3.19K
Enterprise Value/Ebitda-1.63
Forecast
1Y Price Target
$42.44Price Target Upside210.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-4.56
Revenue Forecast (FY)N/A
Avalo Therapeutics Business Overview & Revenue Model
Company Description
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-...
How the Company Makes Money
As a clinical-stage biotech, Avalo Therapeutics has historically not relied on recurring product sales; detailed, current revenue composition from commercial products is null. In general, companies at this stage fund operations primarily through c...
Avalo Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 59.00K | 441.00K | 1.92M | 18.05M | 5.40M |
| Gross Profit | -285.00K | 807.00K | 640.00K | 14.62M | 3.91M |
| EBITDA | -72.92M | -68.34M | -23.29M | -37.27M | -80.48M |
| Net Income | -78.26M | -35.13M | -31.54M | -41.66M | -84.38M |
Balance Sheet | |||||
| Total Assets | 116.46M | 150.73M | 20.99M | 33.37M | 80.21M |
| Cash, Cash Equivalents and Short-Term Investments | 98.34M | 134.55M | 7.42M | 13.17M | 54.59M |
| Total Debt | 2.43M | 568.00K | 537.00K | 19.95M | 33.32M |
| Total Liabilities | 33.41M | 17.70M | 13.69M | 44.28M | 57.13M |
| Stockholders Equity | 83.05M | 133.03M | 7.30M | -10.91M | 23.08M |
Cash Flow | |||||
| Free Cash Flow | -51.46M | -49.06M | -30.84M | -26.85M | -71.00M |
| Operating Cash Flow | -51.46M | -49.06M | -30.68M | -26.75M | -70.89M |
| Investing Cash Flow | -81.72M | 356.00K | -133.00K | -95.00K | -113.00K |
| Financing Cash Flow | 14.59M | 175.85M | 25.04M | -14.70M | 106.76M |
Avalo Therapeutics Technical Analysis
Negative
13.66
Price Trends
15.45
Negative
16.45
Negative
13.56
Positive
Market Momentum
-0.28
Positive
40.56
Neutral
13.59
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVTX, the sentiment is Negative. The current price of 13.66 is below the 20-day moving average (MA) of 14.80, below the 50-day MA of 15.45, and above the 200-day MA of 13.56, indicating a neutral trend. The MACD of -0.28 indicates Positive momentum. The RSI at 40.56 is Neutral, neither overbought nor oversold. The STOCH value of 13.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AVTX.
Avalo Therapeutics Risk Analysis
Avalo Therapeutics disclosed 64 risk factors in its most recent earnings report. Avalo Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Avalo Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $173.82M | -1.38 | -65.76% | ― | ― | -17.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $237.69M | -2.69 | -656.82% | ― | ― | 3.70% | |
50 Neutral | $186.72M | -3.95 | -977.67% | ― | ― | 17.36% | |
48 Neutral | $487.25M | -40.48 | -110.72% | ― | ― | 77.08% | |
47 Neutral | $311.29M | -3.11 | -77.91% | ― | -76.59% | 94.03% | |
46 Neutral | $72.98M | ― | 9999.00% | ― | -96.91% | 63.11% |
* Healthcare Sector Average
AVTX
Avalo Therapeutics
13.66
8.28
153.90%
CRBP
Corbus Pharmaceuticals
9.80
4.00
68.97%
FBRX
Forte Biosciences
35.09
29.50
527.73%
MIST
Milestone Pharmaceuticals
2.02
1.19
143.37%
ELTX
Elicio Therapeutics
10.15
5.23
106.30%
GUTS
Fractyl Health, Inc.
0.46
-0.53
-53.54%
Avalo Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Avalo Therapeutics Highlights AVTX-009 Progress in HS
Positive
Jan 12, 2026
Avalo Therapeutics has released an updated investor presentation in January 2026 detailing progress on AVTX-009, its lead anti-IL-1β monoclonal antibody candidate, which it is positioning as a potential best-in-class and best-in-disease thera...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.